Trust Co. of Vermont Acquires New Holdings in Merck & Co., Inc. $MRK

Trust Co. of Vermont bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 106,435 shares of the company’s stock, valued at approximately $13,677,000.

Other hedge funds have also recently bought and sold shares of the company. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. in the 4th quarter valued at $26,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. in the 4th quarter worth $26,000. High Note Wealth LLC boosted its stake in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the 4th quarter worth about $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive topline INTerpath-001 results strengthened expectations that the vaccine could extend KEYTRUDA’s growth runway and create a potentially important new oncology franchise. Merck Surges on a Melanoma Win
• Positive Sentiment: Analysts raised their valuation expectations: Wolfe Research increased its price target to $180 and assigned an “outperform” rating, while Argus raised its target to $170 and reiterated a “buy” rating. Wolfe Research Price Target
• Positive Sentiment: Investors are also anticipating a concentrated series of regulatory decisions and clinical readouts this fall, which could produce additional upside if Merck’s pipeline delivers. What Would It Take to Get MRK Stock to $200?
• Neutral Sentiment: The cancer-vaccine opportunity remains early. The available evidence is limited, and potential barriers include manufacturing complexity, cost, patient selection, and the need for regulatory review and broader clinical validation. How the Merck/Moderna Cancer Vaccine Works
• Negative Sentiment: After the recent rally, MRK is trading near or above several analysts’ prior targets, leaving less room for disappointment and making future gains increasingly dependent on successful trial results, FDA decisions, and evidence that the post-KEYTRUDA growth strategy can scale.

Insiders Place Their Bets

In other news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president directly owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. The trade was a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 over the last three months. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $156.54 on Wednesday. The company’s 50-day moving average is $129.64 and its 200-day moving average is $121.80. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm has a market capitalization of $386.22 billion, a PE ratio of 125.23, a PEG ratio of 6.32 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on MRK shares. Royal Bank Of Canada lowered Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and boosted their price target for the company from $142.00 to $150.00 in a report on Thursday, August 20th. CICC Research began coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Scotiabank lifted their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Finally, Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $147.60.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.